Search
luspatercept-aamt (Reblozyl)
Indications:
- beta-thalassemia
- myelodysplastic syndrome after epoietin-alfa failure [3]
Dosage:
- 1 mg/kg SC every 3 weeks
Injection: 75 mg lyophilized powder in a single-dose vial
Adverse effects:
- headache, bone pain, arthralgia,
- fatigue, cough
- abdominal pain, diarrhea
- dizziness
Mechanism of action:
- recombinant fusion protein that binds several endogenous TGF-beta superfamily ligands, thus diminishing Smad2/3 signaling
- promotes erythroid maturation through differentiation of normoblasts in mice.
General
recombinant protein; chimer
hematologic agent
References
- RxNorm
- FDA Drug Approval. Nov 8m 2019
FDA approves luspatercept-aamt for anemia in patients with beta thalassemia.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-luspatercept-aamt-anemia-patients-beta-thalassemia
- European Society of Medical Oncology
Myelodysplastic Syndromes Clinical Practice Guidelines (ESMO, 2021)
Medscape - Feb 03, 2021.
https://reference.medscape.com/viewarticle/944879
- Highlights of Prescribing Information.
REBLOZYL (luspatercept-aamt) for injection, for subcutaneous use
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761136lbl.pdf